ERS 2026
European Respiratory Society (ERS) Congress 2026
September 5-9, 2026 | Barcelona, Spain
Tozorakimab significantly reduces COPD exacerbations across a broad patient population: The phase 3 OBERON and TITANIA studies
Twice-yearly depemokimab sustains 2-year response in uncontrolled asthma: SWIFT/AGILE responder analysis
FF/UMEC/VI associated with clinical remission and improved outcomes in uncontrolled asthma: Results from a real-world US study
Updated ERS guidelines on sotatercept in the risk-based management of PAH